Your browser doesn't support javascript.
loading
Low muscle mass measured at T12 is a prognostic biomarker in unresectable oesophageal cancers receiving chemoradiotherapy.
McSweeney, Dónal Michael; Raby, Sophie; Radhakrishna, Ganesh; Weaver, Jamie; Green, Andrew; Bromiley, Paul Alan; van Herk, Marcel; McWilliam, Alan.
Affiliation
  • McSweeney DM; Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK; Radiotherapy Related Research, The Christie Foundation Trust, Manchester M20 4BX, UK. Electronic address: donal.mcsweeney@manchester.ac.uk.
  • Raby S; Department of Clinical Oncology, The Christie Hospital NHS Foundation Trust, Manchester M20 4BX, UK.
  • Radhakrishna G; Department of Clinical Oncology, The Christie Hospital NHS Foundation Trust, Manchester M20 4BX, UK.
  • Weaver J; Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, Manchester M20 4BX, UK.
  • Green A; Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK; Radiotherapy Related Research, The Christie Foundation Trust, Manchester M20 4BX, UK.
  • Bromiley PA; Division of Informatics, Imaging and Data Sciences, University of Manchester, M13 9PL, UK.
  • van Herk M; Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK; Radiotherapy Related Research, The Christie Foundation Trust, Manchester M20 4BX, UK.
  • McWilliam A; Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK; Radiotherapy Related Research, The Christie Foundation Trust, Manchester M20 4BX, UK.
Radiother Oncol ; 186: 109764, 2023 09.
Article in En | MEDLINE | ID: mdl-37385375
ABSTRACT
BACKGROUND AND

PURPOSE:

Low muscle mass is an imaging biomarker of patient frailty that has been associated with increased toxicity and decreased survival in a number of cancers. Patients with unresectable oesophageal cancer receive chemoradiotherapy as standard of care. Muscle mass is not yet an established prognostic marker in this population. Muscle mass is usually assessed by segmenting skeletal muscle at the L3 vertebral level. But radiotherapy planning scans for oesophageal cancers do not always image this level, which has limited previous studies of body composition. Skeletal muscle is known to regulate immune function, but the association of muscle mass with lymphopenia in cancer patients has not been shown. MATERIALS AND

METHODS:

We retrospectively analyse 135 oesophageal cancer patients who received chemoradiotherapy and investigate the prognostic value of skeletal muscle area assessed at T12. We also examine the association between muscle mass and radiation-induced lymphopenia.

RESULTS:

We find that low muscle mass is associated with poorer overall survival (hazard ratio [95% confidence interval] 0.72 [0.53-0.97]). However, this effect interacts with body mass index (BMI) such that the prognostic value of low muscle mass is removed by high BMI. In our study, patients with low muscle mass were more prone to radiation-induced lymphopenia (75% vs. 50% in patients with high muscle mass). A significant decrease in circulating lymphocytes was associated with poorer overall survival (hazard ratio [95% confidence interval] 0.68 [0.47-0.99]).

CONCLUSION:

Our study shows that assessing muscle mass at T12 is feasible and provides prognostic information. Low muscle mass at T12 is associated with poorer overall survival and increased risk of radiation-induced lymphopenia. Muscle mass provides additional information over performance status and BMI. Low BMI patients are most affected by low muscle mass, highlighting the importance of close nutritional support in this population.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms / Sarcopenia / Lymphopenia Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Radiother Oncol Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms / Sarcopenia / Lymphopenia Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Radiother Oncol Year: 2023 Document type: Article